B
Bull
Bull · 25%ITRM
$0.98
Precio del escenario
$0.030
-0.017 (-57.39%)Al cierre
Loading chart…
- High
- 0.047
- Open
- 0.042
- VWAP
- 0.04
- Vol
- 65.74M
- Mkt Cap
- 19.87M
- Low
- 0.028
- Amount
- 2.31M
- EV/EBITDA, TTM
- -0.13
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
AI analysis of Iterum Therapeutics PLC (ITRM)
sellIterum Therapeutics PLC (ITRM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant challenges, including a potential delisting from Nasdaq, financial instability, and lack of positive trading signals. Additionally, there are no recent positive news or catalysts to support a bullish outlook.
Analyst Ratings (4)
+18233.33% upside
Buy
4 Buy
0 Hold
0 Sell
Current: 0.03
Mínimo
2.00
Promedio
5.50
Máximo
9.00
H.C. Wainwright
Neutral
—
2026-03-30
H.C. Wainwright
2026-03-30
Precio objetivo
—
Neutral
Maxim
Hold
—
2026-03-04
Maxim
2026-03-04
Precio objetivo
—
Hold
HC Wainwright & Co.
Strong Buy
$5
2024-09-10
HC Wainwright & Co.
2024-09-10
Precio objetivo
$5
Strong Buy
HC Wainwright & Co.
Strong Buy
$5
2024-08-15
HC Wainwright & Co.
2024-08-15
Precio objetivo
$5
Strong Buy
HC Wainwright & Co.
Strong Buy
$6
2024-06-21
HC Wainwright & Co.
2024-06-21
Precio objetivo
$6
Strong Buy
Métricas de valoración
The current forward P/E ratio for Iterum Therapeutics PLC (ITRM) is 0.00, compared to its 5-year average forward P/E of -1.42.
Alphio AI Price Scenarios for ITRM
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.503-30stocktwitsPMGC Holdings Unit Amends Clinical Trial Agreement
9.003-30NASDAQ.COMIterum Therapeutics Files for Liquidation Amid Financial Struggles
4.503-30stocktwitsLeading Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Rising Ahead of Market Open
9.003-27NewsfilterIterum Therapeutics Files for Liquidation Amid Financial Struggles
7.003-27moomooITERUM THERAPEUTICS PLC - HEARING FOR WINDING UP PETITION SCHEDULED FOR APRIL 13, 2026 - SEC FILING
ITRM FAQ — answered by Alphio AI
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Iterum Therapeutics PLC (ITRM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant challenges, including a potential delisting from Nasdaq, financial instability, and lack of positive trading signals. Additionally, there are no recent positive news or catalysts to support a bullish outlook.
4 analysts cover ITRM: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.50.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.